Advisory board
Our Advisory Board for 2013 includes:
- Rakesh Dixit, VP, MedImmune
- Regis Sodoyer, Scientist, Sadoyer Aventis
- Naomi Chayen, Professor of Biomedical Sciences, Imperial College
- Trevor Wilkinson, Associate Director, Protein Sciences, MedImmune
- Alastair Lawson, VP Structural Biology, UCB
- Claes Gustaffson, CSO, DNA2.0
- Tariq Ghayur, Senior Research Fellow, Ablynx
- John Lambert, Executive VP R&D, CSO, ImmunoGen
- Serge Muydlermans, Group Leader, VIB
- Florence Salmon, Head Non-Clinical Development, Senior Scientist Product Safety, AMT
- Weiming Xu, Senior Research Associate, University of Sheffield
- Joel Richard, VP Drug Product Development, Ipsen
- Gbolahan Oladiran, Senior Scientist, GSK
- Neeraj Kohli, Group leader, Principal Scientist, Merrimack Pharmaceuticals
- Robert Hayes, VP, Johnson & Johnson
- Vivian Lindo, Associate Director Product Characterisation, MedImmune
- Tudor Avinte, Professor, University of Geneva
- Arne Skerra, Professor TU Munchen, Founder & CEO, XL-protein
- Glen MacDonald, CSO & VP, Viventia
- Aline Miller, Senior Lecturer Biomolecular Engineering, University of Manchester
- Torben Frandsen, VP Preclinical R&D Support, Symphogen
- Rene Hoet, Global Biologics, VP Antibody Lead Discovery, Bayer Healthcare AG, Germany
- Bjoern Voldborg, Head of Protein Production Unit, NNF-Centre for Protein Research, University of Copenhagen
- Ralph Colby, Professor, Penn State University
- Guy Hermans, Principal Scientist, Ablynx
- Chris van der Walle, Principal Scientist, MedImmune
- Bruce Hamiliton, Investigator, GSK
- Dragan Grabulovski, CSO, Covagen
- Patrick Garidel, Head of Biopharmaceutical Basic Development, Boehringer Ingelheim
- Frank Mueller, Senior Manager Biopharmaceutical Products, Minapharm
